Giorgio Giorda

Giorgio Giorda

Auto-generated profile, based on publicly available information

Giorgio Giorda

Centro Riferimento Oncologico-IRCCS, Aviano, Italy

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2019 in New England Journal of Medicine
Verified
Journal Article
Closed access
PHPhilipp Harter
Philipp Harter
JSJalid Sehouli
Jalid Sehouli
DLDomenica Lorusso
Domenica Lorusso
ARAlexander Reuss
Alexander Reuss
IVIgnace Vergote
Ignace Vergote
ABAndreas du Bois
Andreas du Bois
Systematic pelvic and paraaortic lymphadenectomy has been widely used in the surgical treatment of patients with advanced ovarian cancer, although supporting evidence from randomized clinical trials has been limited.

11 June 2013 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
Giorgia MangiliGiorgia Mangili
Giorgia Mangili
JOJessica Ottolina
Jessica Ottolina
AGAngiolo Gadducci
Angiolo Gadducci
GGG Giorda
G Giorda
EBE Breda
E Breda
Domenica LorussoDomenica Lorusso
Domenica Lorusso
The aim of this study is to evaluate the long-term outcome of granulosa cell tumour (GCT) of the ovary in a large series of patients treated in MITO centres (Multicentre Italian Trials in Ovarian Cancer) and to define prognostic parameters for relapse and survival. A retrospective multi-institutional review of patients with GCTs of the ovary treated or referred to MITO centres was conducted. Surgical outcome, intraoperative and pathological findings and follow-up data were analysed. Kaplan–Meier and Cox proportional hazards analyses were used to determine the predictors for survival and recurrence. A total of 97 patients with primary GCT of the ovary were identified. The median follow-up period was 88 months (range 6–498). Of these, 33 patients had at least one episode of disease recurrence, with a median time to recurrence of 53 months (range 9–332). Also, 47% of recurrences occurred after 5 years from initial diagnosis. At multivariate analysis, age and stage were independent poor prognostic indicators for survival; surgical treatment outside MITO centres and incomplete surgical staging retained significant predictive value for recurrence in both univariate and multivariate analyses. This study confirms the generally favourable prognosis of GCTs of the ovary, with 5-year overall survival approaching 97%. Nevertheless, prognosis after 20 years was significantly poorer, with 20-year survival rate of 66.8% and a global mortality of 30–35. These findings support the need for lifelong follow-up even in early-stage GCT.

15 January 2000 in Cancer
Verified
Journal Article
Open access
PDF file
CSCarlo Scarabelli
Carlo Scarabelli
AGAngelo Gallo
Angelo Gallo
SFSilvia Franceschi
Silvia Franceschi
ECElio Campagnutta
Elio Campagnutta
GPGiovanni De Piero
Giovanni De Piero
Antonino CarboneAntonino Carbone
Antonino Carbone
BACKGROUND The impact of radical bowel resection with multiple organ resection on the survival if patients with advanced ovarian carcinoma has not been well defined. The authors investigated whether primary cytoreductive surgery including rectosigmoid colon resection would affect the recurrence free interval and survival of these patients. METHODS Between April 1990 and April 1997, 66 previously untreated Stage IIIC–IV ovarian carcinoma patients with macroscopic involvement of the rectosigmoid colon were enrolled. All patients underwent cytoreductive surgery with rectosigmoid colon resection to remove residual tumor less than 2 cm in greatest dimension and received 6 cycles of cisplatin‐based postoperative chemotherapy. RESULTS The median follow‐up was 26 months (range, 7–104 months). In multivariate analysis, residual disease and depth of tumor infiltration of the bowel wall were independently associated with overall survival and recurrence free interval. Disease stage was independently associated only with overall survival. Residual tumor was the most strongly predictive factor for recurrence or death. The 2‐year estimated survival rates according to the amount of residual tumor were 100% for 24 patients with no macroscopic residual disease and 77.3% for 28 patients with residual disease less than 1 cm. None of the 14 patients with residual disease larger than 1 cm were alive 2‐years after operation. Overall, 48 patients (72.7%) developed disease recurrence: 43 (65.1%) in the abdomen, 19 (29.8%) in the liver, and 3 (4.5%) in the pelvis. CONCLUSIONS The current findings suggest that cytoreductive surgery with rectosigmoid colon resection should be considered for ovarian carcinoma patients with bulky pelvic disease to help ensure that they are left with no residual disease after debulking surgery. Cancer 2000;88:389–97. © 2000 American Cancer Society.

28 November 2016 in Annals of Surgical Oncology
Verified
Journal Article
Open access
PDF file
AGAngelo Di Giorgio
Angelo Di Giorgio
Pierandrea De IacoPierandrea De Iaco
Pierandrea De Iaco
MSMichele De Simone
Michele De Simone
AGAlfredo Garofalo
Alfredo Garofalo
GSGiovanni Scambia
Giovanni Scambia
PSPaolo Sammartino
Paolo Sammartino
Purpose The aim of this study was to help with the process of selecting patients with advanced ovarian cancer to undergo cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy...

4 August 2017 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
ADAlessandra Dall'Acqua
Alessandra Dall'Acqua
MSMaura Sonego
Maura Sonego
IPIlenia Pellizzari
Ilenia Pellizzari
IPIlenia Pellarin
Ilenia Pellarin
Vincenzo CanzonieriVincenzo Canzonieri
Vincenzo Canzonieri
Gustavo BaldassarreGustavo Baldassarre
Gustavo Baldassarre
Epithelial ovarian cancer (EOC) is an infrequent but highly lethal disease, almost invariably treated with platinum‐based therapies. Improving the response to platinum represents a great challenge, since it could significantly impact on patient survival. Here, we report that silencing or pharmacological inhibition of CDK6 increases EOC cell sensitivity to platinum. We observed that, upon platinum treatment, CDK6 phosphorylated and stabilized the transcription factor FOXO3, eventually inducing ATR transcription. Blockage of this pathway resulted in EOC cell death, due to altered DNA damage response accompanied by increased apoptosis. These observations were recapitulated in EOC cell lines in vitro , in xenografts in vivo , and in primary tumor cells derived from platinum‐treated patients. Consistently, high CDK6 and FOXO3 expression levels in primary EOC predict poor patient survival. Our data suggest that CDK6 represents an actionable target that can be exploited to improve platinum efficacy in EOC patients. As CDK4/6 inhibitors are successfully used in cancer patients, our findings can be immediately transferred to the clinic to improve the outcome of EOC patients.

1 July 2013 in Gynecologic Oncology
Verified
Journal Article
Closed access
Giorgia MangiliGiorgia Mangili
Giorgia Mangili
CSCristina Sigismondi
Cristina Sigismondi
LFLuigi Frigerio
Luigi Frigerio
MCMassimo Candiani
Massimo Candiani
ASAntonella Savarese
Antonella Savarese
Domenica LorussoDomenica Lorusso
Domenica Lorusso